UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years

Ophthalmology (Rochester, Minn.), 2021-10, Vol.128 (10), p.1460-1468

2021

Volltextzugriff (PDF)

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

The New England journal of medicine, 2021-11, Vol.385 (21), p.1961-1973

2021

Volltextzugriff (PDF)

Trial by "Firsts": Clinical Trial Design and Regulatory Considerations in the Development and Approval of the First AAV Gene Therapy Product in the United States

Cold Spring Harbor perspectives in medicine, 2023-05, Vol.13 (5), p.a041312

2023

Volltextzugriff (PDF)

The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene

American journal of ophthalmology, 2019-03, Vol.199, p.58-70

2019

Volltextzugriff (PDF)

Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women

Fertility and sterility, 2008-10, Vol.90 (4), p.1132-1138

2008

Volltextzugriff (PDF)

Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach

Menopause (New York, N.Y.), 2008-09, Vol.15 (5), p.885-889

2008

Volltextzugriff (PDF)

The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol

Contraception (Stoneham), 2010, Vol.81 (1), p.41-48

2010

Volltextzugriff (PDF)

Effects of synthetic conjugated estrogens A on sleep quality in postmenopausal women with nocturnal diaphoresis and/or hot flushes: a pilot study

Fertility and sterility, 2007-09, Vol.88 (3), p.654-656

2007

Volltextzugriff (PDF)

Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive

Contraception (Stoneham), 2012-03, Vol.85 (3), p.235-239

2012

Volltextzugriff (PDF)

Understanding the menopausal experiences of professional women

Menopause (New York, N.Y.), 2009-01, Vol.16 (1), p.73-76

2009

Volltextzugriff (PDF)

Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial

Obstetrics and gynecology (New York. 1953), 2012-01, Vol.119 (1), p.78-84

2012

Volltextzugriff (PDF)

Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy

Menopause (New York, N.Y.), 2009-07, Vol.16 (4), p.735-741

2009

Volltextzugriff (PDF)

Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo

Contraception (Stoneham), 2008-02, Vol.77 (2), p.91-96

2008

Volltextzugriff (PDF)

Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens

Contraception (Stoneham), 2008-03, Vol.77 (3), p.162-170

2008

Volltextzugriff (PDF)

Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive

Contraception (Stoneham), 2009-05, Vol.79 (5), p.350-355

2009

Volltextzugriff (PDF)

Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive

Contraception (Stoneham), 2008, Vol.77 (1), p.34-39

2008

Volltextzugriff (PDF)

Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo

Contraception (Stoneham), 2008-08, Vol.78 (2), p.113-119

2008

Volltextzugriff (PDF)

Bleeding patterns in users of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo compared to a conventional 28-day regimen

Contraception (Stoneham), 2007-08, Vol.76 (2), p.171-172

2007

Volltextzugriff (PDF)

Evaluation of the long-term safety of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo

Contraception (Stoneham), 2007-08, Vol.76 (2), p.172-172

2007

Volltextzugriff (PDF)

Effectiveness of a novel home-based testing device for the detection of rupture of membranes

American journal of perinatology, 2009-01, Vol.26 (1), p.45-50

2009

Volltextzugriff (PDF)

A look at the long-term safety of an extended-regimen OC

The Journal of family practice, 2010-05, Vol.59 (5), p.E3-E3

2010

Volltextzugriff (PDF)

Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease

Ophthalmology (Rochester, Minn.), 2021-10, Vol.128 (10), p.1460-1468

2021

Volltextzugriff (PDF)

How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease

Journal of AAPOS, 2019-08, Vol.23 (4), p.e7-e7

2019

Volltextzugriff (PDF)

Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a

Blood, 2017-12, Vol.130, p.604-604

2017

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Female
(18)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Obstetrics & Gynecology
(14)
Adult
(13)
Obstetrics And Gynecology
(12)
Biological And Medical Sciences
(10)
Gynecology. Andrology. Obstetrics
(10)
Medical Sciences
(10)
Adolescent
(8)
Genital System. Reproduction
(7)
Pharmacology. Drug Treatments
(7)
Birth Control
(6)
Ethinyl Estradiol - Administration & Dosage
(6)
Hormonal Contraception
(6)
Middle Aged
(6)
Double-Blind Method
(5)
Levonorgestrel - Administration & Dosage
(5)
Pregnancy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

Trial by "Firsts": Clinical Trial Design and Regulatory Considerations in the Development and Approval of the First AAV Gene Therapy Product in the United States

The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene

Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women

Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach

The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol

Effects of synthetic conjugated estrogens A on sleep quality in postmenopausal women with nocturnal diaphoresis and/or hot flushes: a pilot study

Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive

Understanding the menopausal experiences of professional women

Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial

Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy

Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo

Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens

Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive

Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive

Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo

Bleeding patterns in users of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo compared to a conventional 28-day regimen

Evaluation of the long-term safety of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo

Effectiveness of a novel home-based testing device for the detection of rupture of membranes

A look at the long-term safety of an extended-regimen OC

Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease

How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease

Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B - 1 Year Follow up and Impact of Baseline Characteristics on Transgene-Derived Factor IX Activity and Persistence

Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a

Suchergebnisse filtern